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ABSTRACT 
Background: Attention-deficit/hyperactivity disorder (ADHD) is an important modulator of cognitive 
and social functioning in cocaine addiction but it is unclear whether ADHD symptoms and cocaine use 
display mutually aggravating interaction effects on cognition, social functioning and depressive 
symptoms. Therefore, we investigated the interaction of cocaine use and adult ADHD on social and 
non-social cognition and depressive symptoms. 
Methods: Twenty-four cocaine users with (CU+ADHD) and 30 without ADHD (CU-ADHD), 29 
cocaine-naïve ADHD patients, and 40 cocaine-naïve healthy controls underwent comprehensive 
neuropsychological testing including assessment of social cognition (cognitive/emotional empathy and 
Theory-of-Mind). Additionally, depressive symptoms were measured with the Beck Depression 
Inventory.  
Results: The effect size of global cognitive impairment was largest in CU+ADHD (d=1.22 vs. 
controls) followed by CU-ADHD (d=0.74), and cocaine-naïve ADHD patients (d=0.33). A similar 
pattern appeared regarding depressive symptoms (CU+ADHD: d=1.47; CU-ADHD: d=0.49, ADHD: 
d=0.34). In the measures of Theory-of-Mind (CU+ADHD: d=0.76; CU-ADHD: d=0.06, ADHD: 
d=0.01) and cognitive empathy (CU+ADHD: d=0.80; CU-ADHD: d=0.39, ADHD: d=-0.11) only 
CU+ADHD showed moderate to large impairments. Moreover, two‐way analyses of covariance 
revealed a significant interaction effect of the factors ADHD and cocaine use on depressive symptoms 
(p<.05) and Theory‐of‐Mind (p<.05) but not on global cognitive performance (p=.64). 
Conclusions: When occurring together, cognitive impairments associated with both ADHD and 
cocaine use are largely additive, whereas both factors seem to mutually potentiate one another with 
respect to mood and mental perspective-taking disturbances. Given the high comorbidity between 
ADHD and cocaine use, longitudinal studies are needed to investigate the origin of these potentiated 
impairments. 
 
Keywords: stimulants, depression, affective disorder, mentalizing, emotion recognition, chronic use 
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1. INTRODUCTION 
With an estimated 17 million past-year users cocaine remains one of the most used illicit drugs 
worldwide (United Nations Office on Drugs and Crime, 2015). Because of its negative health 
consequences and addictive potential, cocaine use represents a major issue in public health (Nutt et al., 
2007). Attention-deficit/hyperactivity disorder (ADHD) is another major public health issue (Ballon et 
al., 2015), with an estimated worldwide prevalence of about 5% in children (Polanczyk et al., 2014) 
and symptoms that persist into adulthood in up to 65% of patients (Faraone et al., 2006). At more than 
20%, the prevalence of adult ADHD appears to be much higher in individuals with cocaine use 
disorder compared with the general population (Perez de Los Cobos et al., 2011; van Emmerik-van 
Oortmerssen et al., 2012; Vonmoos et al., 2013a). Furthermore, in a sample of adult patients seeking 
treatment for cocaine addiction, 35% were found to have ADHD (Lambert and Hartsough, 1998). 
These numbers are in line with the assumption that adolescents with ADHD are about twice as likely 
as healthy individuals to develop a substance use disorder (Biederman et al., 1995). 
Recent findings from the Zurich Cocaine Cognition Study (ZuCo2St) confirmed that recreational and 
dependent cocaine users displayed considerable impairments in attention, working memory, 
declarative memory, and executive functions that were aggravated with increased use (Vonmoos et al., 
2013a). Furthermore, recreational and dependent cocaine users showed less emotional empathy, and 
specifically dependent users displayed difficulties in mental and emotional perspective-taking (also 
called “mentalizing” or “Theory-of-Mind”), higher delay aversion, and decreased planning abilities 
(Hulka et al., 2014; Preller et al., 2014). In the ZuCo2St, social and non-social cognition were strongly 
moderated by comorbid ADHD symptoms, since the combination of cocaine use and ADHD 
symptoms was associated with much more pronounced deficits (Preller et al., 2014; Vonmoos et al., 
2013a). 
Cocaine use appears to impact neurotransmitter systems in brain regions thought to be altered in 
ADHD patients: Chronic cocaine use has been linked to alterations in the fronto-striatal dopamine 
system (Beveridge et al., 2008; Garavan and Hester, 2007; Volkow et al., 2009a; Volkow et al., 2004) 
and noradrenergic changes in the thalamus and locus coeruleus (Ding et al., 2010). Moreover, 
structural and functional changes in several areas of the prefrontal cortex have been linked to cognitive 
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deficits in dependent cocaine users (Beveridge et al., 2008; Garavan and Hester, 2007; Goldstein et al., 
2004). Remarkably, fronto-striatal dysfunctions and changes in catecholaminergic neurotransmitter 
systems appear to also play a crucial role in the etiology of ADHD (Brennan and Arnsten, 2008; Del 
Campo et al., 2011; Tripp and Wickens, 2009). In particular, disturbances in cognitive functions such 
as vigilance, working memory, planning, and response inhibition—as well as problems in motivational 
processes, such as delay aversion—are associated with both ADHD (Nigg, 2005; Willcutt et al., 2005) 
and cocaine use (Hulka et al., 2014; Vonmoos et al., 2013a; Vonmoos et al., 2013b). In both cases, 
these effects have been proposed to depend on changes in the dopamine and noradrenaline system 
(Gould et al., 2014; Sofuoglu, 2010; Tripp and Wickens, 2009). Recently, also problems in more 
complex cognitive functions such as social cognition and interaction have been demonstrated in 
recreational and dependent cocaine users as well as in patients with ADHD (Bora and Pantelis, 2016; 
Hulka et al., 2014; 2013; Preller et al., 2014). Additionally, both, patients with cocaine addiction and 
with ADHD have an increased risk for developing depressive symptoms (Connor et al., 2003; 
Rounsaville, 2004; Swendsen and Merikangas, 2000). 
 
To our knowledge, the interaction of ADHD symptoms and cocaine use with regard to cognitive and 
socio-cognitive functions as well as to depressive symptoms has not been investigated in detail yet. 
Thus, it remains unclear whether the pronounced cognitive and socio-cognitive impairments of 
cocaine users with ADHD symptoms arise from a combination of ADHD and cocaine use or can be 
explained by ADHD alone (Preller et al., 2014; Vonmoos et al., 2013a). Therefore, we recruited a 
group of ADHD patients without illegal drug use and compared them with cocaine users with and 
without ADHD and to stimulant-naïve healthy controls so as to investigate the presumed interactions 
between ADHD and cocaine use. We hypothesized that ADHD and cocaine use would reveal 
cumulative or even multiplicative effects.  
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2. METHODS 
2.1 Participants 
We recruited 29 ADHD patients who reported no illegal drug use, 24 cocaine users with ADHD 
(CU+ADHD), 30 cocaine users without ADHD (CU-ADHD), and 40 stimulant-naïve healthy controls 
and matched the groups for age and sex (see Supplementary Methods S1 for recruitment details). All 
participants had to be between 18 and 60 years old and fluent in German. Exclusion criteria for all 
participants were current or previous neurological disorders or head injury, any clinically significant 
medical disease, a family history of schizophrenia or bipolar disorder, and the use of prescription 
drugs affecting the central nervous system (except for methylphenidate and dexamphetamine for the 
ADHD group) as well as a lifetime history of opioid use. For controls and ADHD patients, further 
exclusion criteria were any Axis-I DSM-IV psychiatric disorder (with the exception of ADHD), any 
form of addiction (except nicotine), and regular illegal drug use (lifetime use >15 occasions, except 
cannabis). Specific exclusion criteria for the cocaine user groups were polytoxic drug use, any Axis-I 
DSM-IV adult psychiatric disorder (other than ADHD in CU+ADHD) with exception of cocaine, 
nicotine, and alcohol abuse/dependence and history of depression (acute major depression was 
excluded). Inclusion criteria for the cocaine user groups were cocaine use of at least 0.5g/month, 
cocaine as the preferred illegal drug, and a current abstinence period of less than 6 months. All 
participants were asked to abstain from illegal substances for at least three days and from alcohol for at 
least 24h prior to testing. Compliance was controlled by urine toxicology, and self-reported drug use 
was controlled by a 6-month hair testing (see Supplementary Methods S2). Of the 29 cocaine-naïve 
ADHD patients, 24 received stimulant treatment prior to the study (23 participants received 
methylphenidate, 1 participant received dexamphetamine) while four patients showed no history of 
stimulant medication. ADHD patients were asked not to use prescription stimulants or any other 
medication for 24h prior to testing. The study was approved by the Cantonal Ethics Committee of 
Zurich, and all participants gave written informed consent and were compensated for their 
participation.  
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2.2 Clinical Assessment 
Trained psychologists conducted the Structured Clinical Interview for Axis-I DSM-IV disorders in 
order to exclude participants with an Axis-I DSM-IV psychiatric disorder. Drug use was assessed with 
the Interview for Psychotropic Drug Consumption (Quednow et al., 2004). ADHD diagnoses and 
current severity of ADHD symptoms were evaluated with the ADHD self-rating scale (ADHD-SR) 
(Rosler et al., 2004) corresponding to DSM-IV criteria. Furthermore, the German short version of the 
Wender Utah Rating Scale (WURS-k) measuring ADHD symptoms present in childhood was used in 
the ADHD sample (Retz-Junginger et al., 2002). Depressive symptoms – as an outcome measure - 
were assessed with the Beck Depression Inventory (BDI) (Beck et al., 1961). Premorbid verbal 
intelligence was estimated with a German vocabulary test (Mehrfachwahl-Wortschatz-Intelligenztest) 
(Lehrl et al., 1995). Severity of tobacco dependence was measured by the Fagerström Test of Nicotine 
Dependence (Heatherton et al., 1991). Finally, to measure present cocaine craving in cocaine users, the 
brief version of the cocaine craving questionnaire (CCQ) was applied (Sussner et al., 2006). 
 
2.3 Neuropsychological Assessment 
Cognitive performance was assessed with four tests from the Cambridge Neuropsychological Test 
Automated Battery (Strauss et al., 2006): Rapid Visual Information Processing, Spatial Working 
Memory, Intra/Extra-Dimensional Set Shifting, and Paired Associates Learning. Additionally, a 
German version of the Rey Auditory Verbal Learning Test (Helmstaedter et al., 2001) and the Letter 
Number Sequencing Test were administered (Wechsler, 1997). As previously published (Vonmoos et 
al., 2013a; Vonmoos et al., 2014), 15 predefined test parameters underwent z-transformation on the 
basis of means and standard deviations of the control group and were combined into four cognitive 
domains (Goldstein et al., 2004; Jovanovski et al., 2005; Pace-Schott et al., 2008; Vonmoos et al., 
2013a; Woicik et al., 2009): attention, working memory, declarative memory, and executive functions 
(see Supplementary Methods S3 for details). These four domains were equally integrated into a global 
cognitive index (GCI). To avoid the accumulation of alpha-errors, we focused our analysis on these 
four domains and the GCI. However, we reported single neuropsychological test scores in the 
Supplementary Material (Supplementary Table S1). Two aspects of social cognition—Theory-of-Mind 
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and empathy—were assessed with the Movie for the Assessment of Social Cognition (MASC) 
(Dziobek et al., 2006) and the Multifaceted Empathy Test (MET) (Dziobek et al., 2008), both of which 
have been described in detail in our previous work (see also Supplementary Methods S4) (Preller et 
al., 2014).  
 
2.4 Statistical Analysis 
We performed the statistical analyses with SPSS 22.0 for Windows. Demographic and drug use data 
for all groups were analyzed with Pearson’s chi-square test and analyses of variance (ANOVA) 
followed by Sidak-corrected post-hoc comparisons where appropriate. To investigate group 
differences over all groups in cognitive and emotional parameters, we performed analysis of 
covariance (ANCOVA) or multivariate analysis of covariance (MANCOVA) followed by Sidak-
corrected post-hoc comparisons. To investigate the interaction between cocaine use and ADHD, we 
analyzed the data with two-way ANCOVA using the fixed factors of “ADHD” and “cocaine use” 
(both yes/no). Following significant interaction effects, simple effects were calculated. The 
significance threshold was set at p<.05. To examine if cognitive performance and depressive 
symptoms were associated with craving for cocaine, Pearson’s product moment correlations between 
relevant outcome measures and the CCQ sum score were calculated (Supplementary Table S2). In 
order to avoid alpha-error accumulation, the significance threshold was set to p<.01 for correlation 
analyses. Because age is a common confounding variable in investigations of cognition (and especially 
social cognition), it was introduced as a covariate (Horning et al., 2012; Verhaeghen and Salthouse, 
1997). Because of significant group differences, years of education (YoE) was introduced as a further 
covariate. We have previously shown that the moderating effect of the co-factor ADHD on global 
cognitive performance in cocaine users was large with an effect size of Cohen's f=0.49 and a partial 
eta-square=0.195 (Vonmoos et al., 2013a). In an a priori power analysis, we therefore assumed a lower 
effect size of f=0.40, an α-error probability of 5%, and a conservative power of 90% for the present 
ANCOVA design with 4 groups and 2 covariates, suggesting a total minimum sample size of 93 
individuals.  
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3. RESULTS 
3.1 Demographic Characteristics and Drug Use 
The groups did not differ significantly in age and sex distribution (Table 1). However, the groups 
significantly differed in YoE and verbal IQ: CU+ADHD had fewer YoE and lower verbal IQ scores 
than controls and ADHD patients. As expected, the four groups differed in ADHD symptom severity 
as measured by the ADHD-SR. The ADHD group reported the most severe ADHD symptom scores, 
which differed significantly from controls and CU-ADHD but importantly did not differ significantly 
from CU+ADHD (p=.49). On the WURS-k, the ADHD group reported a mean score of 36.8±15.9 
(SD), which is above the diagnostic cut-off of 30 points (Retz-Junginger et al., 2002). 
Notably, CU-ADHD did not differ significantly from CU+ADHD for any self-reported cocaine use 
parameter or for frequency of DSM-IV cocaine dependence (Table 1). Moreover, CU+ADHD and CU-
ADHD showed no significant differences regarding cocaine hair concentrations or frequency of 
cocaine-positive urine testings. Accordingly, CU-ADHD and CU+ADHD did also not differ 
significantly in the CCQ sum score. In addition, correlation analysis showed that test performance and 
depressive symptom scores did not correlate with craving for cocaine (Supplementary Table S2). Hair 
testings confirmed a clear preference for cocaine versus other drugs for both groups (Supplementary 
Table S3) and revealed the highest methylphenidate concentrations in ADHD patients (Table 1). 
CU+ADHD and CU-ADHD smoked significantly more cigarettes than the ADHD patients, and 
CU+ADHD also smoked more frequently than controls. Both cocaine user groups reported greater 
weekly alcohol consumption than the ADHD group.  
 
3.2 Cognition 
One-way ANCOVAs (with YoE and age as covariates) performed for the GCI and the four cognitive 
domains revealed significant group differences in the GCI (F(3,117)=12.12, p<.001), working memory 
(F(3,117)=8.87, p<.001), declarative memory (F(3,117)=14.07, p<.001), executive functions 
(F(3,117)=2.68, p<.05), and the attention domain score (F(3,117)=4.16, p<.01). In addition, clear 
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linear trends (controls>ADHD>CU-ADHD>CU+ADHD) were found (p<.001–.01) in all cognitive 
domains (Fig. 1). 
Sidak post-hoc comparisons revealed significant differences between controls and both cocaine-using 
groups in the GCI, working memory, and declarative memory (p<.001–.01), indicating cognitive 
impairments in both user groups. CU+ADHD also differed from controls in attention (p<.01) and 
performed worse than the ADHD group in the GCI and the two memory domains (p<.001–.01). CU-
ADHD performed better than CU+ADHD for declarative memory (p<.05) (Fig. 1). ADHD patients 
showed no significant performance deficits compared with the controls in any of the four domains or 
the GCI. 
 
A two-way ANCOVA revealed significant main effects of ADHD (F(1,117)=7.62, p<.01) and cocaine 
use (F(1,117)=28.49, p<.001) on the GCI but no significant interaction effect (F(1,117)=.21, 
p=.64)(Fig. 2a). Similar effects were found for the other domains—except for attention and executive 
functions, for which the main effects for ADHD were not significant (F(1,117)=2.58 and 0.61, p=.11 
and .44, respectively). 
 
3.3 Social cognition  
The MANCOVA (with YoE and age as covariates) performed for the z-transformed variables 
cognitive empathy (CE), explicit emotional empathy (EEE), and implicit emotional empathy (IEE) on 
the MET showed a significant main effect for group using Hotelling’s trace (V=.21, F(9,341)=2.66, 
p<.01). Groups differed significantly in CE (F(3,117)=4.62, p<.01). In addition, linear trends 
(controls>ADHD>CU-ADHD>CU+ADHD) were found (p<.001–.05) for all of the three MET 
variables. For Theory-of-Mind, an ANCOVA revealed significant group differences (F(3,117)=3.68, 
p<.05) in the MASC sum score (Supplementary Fig. S1) and a significant linear trend (p<.01, 
controls>ADHD>CU-ADHD>CU+ADHD). Sidak post-hoc comparisons revealed that CU+ADHD 
made more errors than controls and ADHD patients in CE and Theory-of-Mind (p<.01–.05) and that 
CU-ADHD performed better than CU+ADHD on the MASC (p<.05). Analysis of the different MASC 
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error types are shown in the Supplementary Material (Supplementary Fig. S2). Notably, ANCOVA for 
overmentalizing errors (excessive Theory-of-Mind) yielded a significant main effect for group 
(F(3,117)=4.08, p<.01), and Sidak post-hoc comparisons revealed significant differences between 
CU+ADHD and ADHD patients and between CU+ADHD and controls (p<.01 and <.05). 
 
Two-way ANCOVAs on the MET scores revealed a significant main effect for cocaine use on CE 
(F(1,117)=12.65, p<.001) and IEE (F(1,117)=7.70, p<.01) but not on EEE (F(1,117)=3.61, p=.06). For 
ADHD, no significant main effects were found (F(1,117)=0.02–0.85, p=.36–.88), and the two factors 
showed no significant interaction effects (F=(1,117)=0.18–2.16, p=.14–.67). 
The two-way ANCOVA on Theory-of-Mind revealed that the interaction of ADHD and cocaine use 
had a significant effect on mental and emotional perspective-taking performance (F(1,117)=4.09, 
p<.05). The main effects for ADHD (F(1,117)=3.93, p<.05) and cocaine use (F(1,117)=5.21, p<.05) 
were also significant (Fig. 2b). Simple effect analysis revealed that cocaine users did not differ from 
non-users in the no ADHD group (F(1,117)=0.20, p=.66), whereas cocaine use was associated with a 
significantly worse performance in the ADHD group (F(1,117)=7.23, p<.01). 
Finally, a significant ADHD*cocaine use interaction effect (F(1,117)=4.84, p<.05) (Supplementary 
Fig. S3), as well as a main effect for cocaine on overmentalizing errors (F(1,117)=8.57, p<.01) 
appeared. The tendency to overmentalize was higher in cocaine users compared to non-users among 
the participants with ADHD (F(1,117)=10.86, p<.001). 
 
3.4 Depressive Symptoms 
The ANCOVA (with YoE and age as covariates) for the BDI score showed a significant main effect 
for group (F(3,117)=13.82, p<.001) as well a significant linear trend (controls<ADHD<CU-
ADHD<CU+ADHD) (p<.001) (Fig. 3). CU+ADHD showed increased BDI scores versus all three 
other groups (p<.001). The two-way ANCOVA revealed significant main effects for ADHD 
(F(3,117)=17.33, p<.001) and cocaine use (F(1,117)=24.24, p<.001) and a significant interaction 
effect (F(1,117)=4.06, p<.05) (Fig. 2c), indicating an amplification of emotional disturbances in the 
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CU+ADHD group compared with the other three groups. Simple effect analyses showed that cocaine 
use is associated with significantly higher BDI scores in individuals with (F(1,117)=18.47, p<.001) 
and without ADHD (F(1,117)=7.58, p<.01). 
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4. DISCUSSION 
The aim of the study was to investigate the interaction between ADHD and cocaine use with regard to 
non-social and social cognition and depressive symptoms. Detailed psychiatric diagnostics and hair 
toxicology were used to minimize the influence of psychiatric comorbidities and polytoxic drug use. 
We were able to demonstrate that cocaine users with ADHD symptoms (CU+ADHD) show stronger 
cognitive impairments than cocaine users without ADHD (CU-ADHD) or ADHD patients without 
cocaine use. Considering the increase in effect size, our data suggest that the combined detrimental 
effects of ADHD and cocaine on cognition are largely additive and that the factors seem to potentiate 
each other regarding depressive symptoms and mentalizing deficits. Thus, we supported our previous 
assumption that ADHD and cocaine use might exert mutually aggravating effects on cognitive 
performance and mental perspective-taking (Preller et al., 2014; Vonmoos et al., 2013a). Finally, adult 
ADHD patients without illicit drug consumption do not display impairments regarding cognitive and 
emotional empathy or mental and emotional perspective-taking. 
 
Our study supports the hypothesis that the interaction of ADHD and cocaine use has a summative 
effect on general cognitive performance. Furthermore, we found only small to moderate performance 
deficits across all cognitive domains (d=0.17–0.37) in our sample of cocaine-naïve adults with ADHD. 
However, in addition to the limited power, rather small effect sizes can be expected in the executive 
functions of adult ADHD patients because of improved compensation for possible deficits with age 
(Nigg et al., 2005). Most studies reporting executive function deficits in adult ADHD patients have not 
assessed comorbidities, which may account for many findings of executive impairments (Nigg et al., 
2005). Furthermore, previous findings suggest that declarative memory deficits are common in adult 
ADHD (Verster et al., 2010), which is in line with the present results: Our ADHD patients showed the 
strongest, although still not significant, impairment in this domain. Surprisingly, we did not find strong 
impairments in the attention domain, as might be expected in a disorder defined by attentional deficits. 
However, the distinction between adult ADHD patients and controls is usually based on omission 
errors and variability in reaction times in sustained attention and selective tasks over a minimum of 14 
minutes (Conners and Sitarenios, 2011; Hervey et al., 2004). By contrast, our attention domain 
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included two parameters of a sustained attention task of a maximum length of 5 minutes and a 
supraspan parameter of a verbal learning task, which required less than 2 minutes. Furthermore, most 
of our cocaine-naive ADHD patients received pharmacological treatment with prescription stimulants 
prior to the study, which might have led to an underestimation of their potential cognitive deficits. 
However, acute cognitive improvements in adult ADHD patients medicated with methylphenidate 
should be expected primarily in the attention domain—less so in other cognitive domains (Advokat, 
2010). On the other hand, because we asked our ADHD patients to abstain from their daily stimulant 
medication for at least 24h so as to exclude acute drug effects, the beneficial effects of 
methylphenidate are expected to no longer be present at the time of testing. Moreover, it should be 
noticed that our ADHD patients but also our cocaine using groups had a high level of functioning as 
all of the ADHD patients as well as 80% of the cocaine users were employed. 
 
We have previously shown that dependent and recreational cocaine users display impaired explicit and 
implicit emotional empathy (Preller et al., 2014). Probably owing to the smaller sample sizes of the 
present cocaine groups and the mixture of recreational and dependent cocaine users, the present study 
showed only moderate effect sizes (d=0.24-0.55), which were, however, in the same range as reported 
in our previous publication (Preller et al., 2014). Furthermore, we previously demonstrated that 
CU+ADHD but not CU-ADHD individuals show significant mental perspective-taking deficits (as 
measured by MASC) (Preller et al., 2014), which is in line with the present results coming from an 
overlapping sample. Accordingly, the two-way ANCOVA of the MASC sum score revealed that the 
observed drop in performance in CU+ADHD can be explained by the mutual interaction of cocaine 
use and ADHD. Interestingly, it is not a general lack of Theory-of-Mind that accounts for group 
differences but rather the tendency of CU+ADHD to overmentalize. Thus, CU+ADHD might fail to 
understand the perspective of others because they overinterpret social signs (Preller et al., 2014). 
 
The literature on social cognition in adult ADHD is surprisingly sparse and even in children with 
ADHD, empathy and Theory-of-Mind have rarely been investigated (Uekermann et al., 2010). 
However, there is some evidence that empathy and Theory-of-Mind may be affected in children with 
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ADHD (Braaten and Rosen, 2000; Buitelaar et al., 1999; Dyck et al., 2001). Because social cognition 
is essential for successful social interactions, the adult patients in our sample have perhaps developed 
strategies to compensate for possible social cognitive deficits. This may explain the lack of 
performance differences in social cognition in comparison to controls.  
 
Regarding depressive symptoms, CU+ADHD displayed higher BDI scores than the controls, the 
ADHD patients, and CU-ADHD, indicating increased emotional burdens in CU+ADHD. Furthermore, 
a significant interaction effect indicated that cocaine use and ADHD mutually potentiate depressive 
symptoms. This finding is in line with the frequent comorbidity between depression and ADHD, as 
well as between depression and substance use disorders (Abraham and Fava, 1999; Daviss, 2008; 
Swendsen and Merikangas, 2000). Moreover, there is evidence for a relationship between depression 
and trait impulsivity (Swann et al., 2008), a core feature of ADHD (Wilson, 2007) that is also elevated 
in cocaine users (Vonmoos et al., 2013b).  
 
As mentioned in the Introduction, there are potential commonalities between ADHD and cocaine use 
at the level of their neurobiological basis. The majority of imaging studies describes increased 
dopamine transporter density; decreased dopamine D2 receptor availability; and decreased dopamine 
synthesis, storage, and release in both ADHD patients and chronic cocaine users (Trifilieff and 
Martinez, 2013; Zimmer, 2009). However, some conflicting results have been found regarding 
dopamine transporter density and the availability of D2 receptors in ADHD patients (Volkow et al., 
2009b), whereas for chronic cocaine users, the results seem to be more consistent. Additionally, recent 
data from our lab suggest that cognitive impairments in cocaine users are likely drug-induced 
(Vonmoos et al., 2014), whereas cognitive dysfunctions in ADHD should be inherent clinical features 
of the syndrome (Biederman, 2005). We therefore propose that cocaine-induced neurochemical 
adaptations amplify the ADHD-related abnormalities of the monoamine neurotransmitter systems 
(Tripp and Wickens, 2009). Although cocaine seems to deteriorate further the cognitive abilities of 
ADHD patients, the stimulant methylphenidate, which is used to target the cognitive problems of 
ADHD patients, has not been shown to lead to such an interaction (yet). This might be explained by 
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the different pharmacokinetics of these two substances. The strong cocaine-induced peaks of 
neurotransmitter release (Nestler, 2005) and the fast clearance of the drug seem to be more 
problematic with regard to neurochemical changes and associated cognitive dysfunctions than the 
slower brain uptake and clearance for (orally consumed) methylphenidate (Volkow et al., 1995; 
Volkow et al., 1998).  
 
The current study has some limitations. Recent findings suggest that a single factor may account for 
interindividual variance in general psychopathology (e.g., Caspi’s p-factor) (Caspi et al., 2014). Thus, 
the members of the CU+ADHD group might be more fraught in terms of general psychopathology 
than the CU-ADHD or ADHD patients. Because it is impossible to rule out this possibility in a study 
with a cross-sectional design, longitudinal investigations are needed on the interaction of cocaine use 
and ADHD. Furthermore, most of the ADHD patients in this study were previously medicated with 
prescription stimulants, whereas the CU+ADHD individuals were not (see above). However, at the test 
session they were abstinent for at least 24h. Thus, further investigations on the interaction of ADHD 
and cocaine should focus on unmedicated ADHD patients. Finally, the CU+ADHD displayed a more 
severe pattern of substance use specifically with regard to cannabis. Thus, it is not fully clear how 
cannabis use interacts with cocaine and ADHD on cognition. However, all relevant effect sizes 
remained the same if weekly cannabis use was introduced as a further covariate. 
 
In conclusion, our data indicate that cognitive and social deficits are considerably worse in cocaine 
users with ADHD in comparison to cocaine users without ADHD and to ADHD patients without 
cocaine use. The cognitive impairments of ADHD and cocaine use seem to be additive, whereas 
cocaine use and adult ADHD appear to mutually amplify emotional disturbances and perspective-
taking deficits in cocaine users with ADHD. Given the considerable comorbidity between ADHD and 
cocaine use disorder (Katusic et al., 2005; Wilens, 2007), longitudinal studies are needed to investigate 
the causal relationship behind the interaction of cocaine use and ADHD. Additionally, the impact of 
substances such as tobacco, alcohol and cannabis on cognitive and socio-cognitive deficits as well as 
on depressive symptoms need further investigation specifically in individuals with ADHD and cocaine 
16 
 
 
use. Finally, the present data strongly suggest that ADHD patients should be better informed about 
their specific cognitive and emotional risks of cocaine abuse. 
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Table 1: Demographic data and drug use (means and standard deviations) 
 Controls ADHD CU-ADHD CU+ADHD F χ2 t test df, dferr p 
n (%) 40 (32.5) 29 (23.5) 30 (24.5) 24 (19.5)      
Age, years 26.1 (5.5) 25.7 (6.3) 26.9 (6) 27.7 (6.6) 0.59   3, 119 .625 
Sex (female/male) 22/18 17/12 13/17 6/18  7.42  3 .060 
Years of education  11.5 (1.6) 11.7 (1.8) 11 (1.9) 10.2 (1.4)*†† 4.49   3, 119 .005 
Verbal intelligence 104.3 (8.1) 104.6 (9.7) 101.6 (10) 97.8 (7.7)*† 3.39   3, 119 .020 
ADHD-SR 7.5 (5.3) 29.2 (10.9)*** 11.1 (7.3)††† 25.7 (8.2)***‡‡‡ 57.05   3, 119 .000 
Craving for Cocaine (0-70) - - 18.3 (8.5) 23.3 (12.9)   -1.74 52 .088 
          
Tobacco          
Smoking status (y/n)a 22/18 11/18 19/11 19/5  9.69  3 .021 
Dependence (y/n)b 9/31 3/26 15/15 10/14  13.66  3 .003 
Cigarettes per day 5.3 (7.5) 2.7 (5.7) 11 (12.1)†† 13 (10.2)**††† 7.87   3, 119 .000 
Years of use 5.3 (5.5) 4.7 (7.4) 7.7 (7) 10.6 (6.1)*†† 4.71   3, 119 .004 
          
Alcohol          
Alcohol use (y/n)a 39/1 29/0 30/0 24/0  2.09   .554 
Dependence (y/n)c 0/40 1/28 4/26 2/22  6.26  3 .100 
Grams per weeka 110.6 (147.2) 53.1 (40.2) 194.4 (238.5)†† 177.2 (146.7)† 4.77   3, 119 .004 
Years of use 7.9 (4.4) 7.7 (6.7) 9.6 (5.1) 10.6 (5.4)† 1.91   3, 119 .131 
          
Cocaine          
Dependence (y/n)c - - 6/24 7/14  0.61  1 .528 
Grams per weeka - - 2.3 (3.1) 2.1 (3.1)   0.27 52 .789 
Years of use - - 6.3 (5.1) 7 (4.9)   -0.53 52 .599 
Last consumption (days) - - 22.3 (33) n=30 26.6 (35.1) n=24   -.47 52 .643 
Cumulative dose (grams) - - 1932.6 (5169.8) 3174.2 (8456)   -0.67 52 .509 
Positive urine testd(%) 0 (0) 0 (0) 8 (27.6) 5 (20.8)  .32  1 .570 
Hair analysis pg/mge 0 (0) 0 (0) 5212.8 (9195.6) 5509.8 (9517.2) 7.47   3, 118 .000 
          
Methylphenidate          
Tablets per weeka,f 0 (0) 15.9 (18.4) 0.9 (2.9)††† 1.9 (4)††† 20.17   3, 119 .000 
Years of use 0 (0) 2.6 (3.7) 0.1 (0.3)††† 0.1 (0.2)††† 15.44   3, 119 .000 
Last consumption (days)  8.8 (19.4) n=24 48.3 (53.7) n=5    -2.94 27 .007 
Cumulative dosef 0 (0) 2001 (2672) 36.8 (124.9)††† 49.3 (133.3)††† 17.12   3, 119 .000 
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Significant p-values are shown in bold. Statistical tests: ANOVA (all groups), χ2 test (all groups or cocaine user groups) for frequency data or independent t test (two groups).  
ADHD, attention-deficit/hyperactivity disorder; ADHD-SR, ADHD self-rating scale; CU+ADHD, cocaine users with ADHD; CU-ADHD, cocaine users without ADHD; MPH, methylphenidate. 
Consumption per week, duration of use, and cumulative dose are averages within the total group. 
Last consumption is an average only for persons who used the drug within the past 6 months. In this case, sample size (n) is shown. 
a During the past 6 months. 
b Fagerström Test > 2 points. 
c According to DSM-IV criteria. 
d For cut-offs, see the Supplementary Methods S2. One urine sample (CU-ADHD) was missing. 
e One hair sample (ADHD) is missing. 
f In 10-mg tablets. 
Sidak post-hoc tests vs. controls: *p<.05, ** p <.01; vs. ADHD † p <.05, †† p <.01, ††† p <.001; vs. CU-ADHD: ‡‡‡ p <.001
Urine toxicology MPH ng/ml na 1.14 (3.4) n=27 na na      
Urine tox. Ritalin acid ng/ml na 327.94 (721.8) n=27 na na      
Hair analysis pg/mge 0 (0) 191 (342.4) 15.8 (77.8) 0 (0) 8.84   3 .000 
          
Cannabis          
Grams per weeka 0.2 (0.6) 0.1 (0.4) 0.2 (0.3) 2.2 (4.3)***†††‡‡‡ 7.45   3, 119 .000 
Years of use 3.5 (4.2) 2.7 (4.3) 6.6 (5.1)† 8.2 (6.5)**††† 7.69   3, 119 .000 
Cumulative dose (grams) 919.8 (4372.6) 235.2 (613.7) 972.3 (1658.2) 1989.3 (3303.2) 1.49   3, 119 .222 
Last consumption (days) 35 (43.4) n=17 27.8 (29.7) n=8 25.2 (29.3) n=22 18 (28.3) n=18 0.77   3, 61 .514 
Positive urine testingd (%) 3 (7.5) 3 (10.3) 3 (10.3) 10 (41.7) 15.62   3 .001 
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Figure Captions 
Figure 1: Mean z-scores and standard errors for the four cognitive domains and the global cognitive 
index  
Values corrected for years of education and age. Sidak post-hoc tests vs. controls: **p<.01, 
***p<.001; vs. ADHD: ††p<.01, †††p<.001; vs. CU-: ‡p<.05. Cohen’s d effect sizes for group 
comparisons vs. controls are shown. 
 
Figure 2: Mean scores and standard errors for a) the global cognitive index (GCI), b) Theory-of-
Mind, and c) the Beck Depression Inventory (BDI) for all participants (n=123) 
Two-way analysis of covariance (ANCOVA) revealed summative effects of ADHD and cocaine use 
on cognition (p>.05). However, these two factors show a significant interaction effect on Theory-of-
Mind and depressive symptoms (both p<.05), indicating a mutual reinforcement. ADHD = attention-
deficit/hyperactivity disorder, MASC = Movie for the Assessment of Social Cognition. 
 
Figure 3: Mean sum score and standard errors for the Beck Depression Inventory 
Values corrected for years of education and age. Sidak post-hoc tests vs. controls: ***p<.001; vs. 
ADHD: †††p<.001; vs. CU: ‡‡‡p<.001. Cohen’s d effect sizes for group comparisons vs. controls are 
also shown. 
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Methods S1: Recruitment and selection 
Out of the already existing pool of participants from the Zurich Cocaine Cognition Study (ZuCo2St) 
(Preller et al., 2014; Vonmoos et al., 2014), 24 cocaine users with ADHD (CU+ADHD), 30 cocaine 
users without ADHD (CU-ADHD), and 22 stimulant-naïve healthy controls were identified for the 
present analyses. Eighteen stimulant-naïve healthy controls and 29 ADHD patients without cocaine 
use were additionally recruited resulting in a total sample of 123 participants consisting of 40 
stimulant-naïve healthy controls, 24 CU+ADHD, 30 CU-ADHD, and 29 ADHD patients without 
cocaine use matched for age and sex. ADHD patients were recruited from the ADHD special 
outpatient clinic of the Department of Psychiatry, Psychotherapy, and Psychosomatics at the 
Psychiatric Hospital of the University of Zurich. Some patients as well as controls were also recruited 
by advertisements in various online media and flyers distributed in various buildings of the University 
of Zurich. Candidates underwent a brief telephone screening to assess their study eligibility. All 
subjects were aged between 18 and 60 years and had sufficient German language skills. In total, 32 
ADHD patients were tested whereof 3 ADHD patients had to be excluded because positive hair 
analyses revealed undeclared drug use contradicting the inclusion criteria (cocaine use or excessive 
MDMA use).  
Methods S2: Urine and hair toxicology 
Urine toxicology analyses comprised the compounds/substances: tetrahydrocannabinol, cocaine, 
amphetamines, benzodiazepines, opioids, and methadone and were assessed by a semi-quantitative 
enzyme multiplied immunoassay method using a Dimension RXL Max (Siemens, Erlangen, 
Germany). For the detection of illegal drug use, the following cut-offs have been applied (Bush, 
2008): Cannabis, 50 ng/ml; cocaine, 150 ng/ml; and amphetamines, 500 ng/ml.  
To objectively characterize drug use over the last six months, hair samples were collected and 
analyzed with Liquid chromatography-tandem mass spectrometry (LC-MS/MS). If participants’ hair 
was long enough, one sample of six cm hair (from the scalp) was taken and subsequently divided into 
two subsamples of three cm length. The following compounds were assessed: cocaine, 
benzoylecgonine, ethylcocaine, norcocaine, amphetamine, methamphetamine, MDMA, MDEA, 
MDA, morphine, codeine, methadone EDDP (primary methadone metabolite), tramadol, and 
methylphenidate.  
For our routine protocol for drugs of abuse analysis a three step washing procedure with water (2 
minutes shaking, 15ml), acetone (2min., 10ml) and finally hexane (2min., 10ml) of hair was 
performed. Then the hair samples were dried at ambient temperatures, cut into small snippets and 
extracted in two steps, first with methanol (5ml, 16 hours, ultrasonication) and a second step with 3 ml 
MeOH acidified with 50 µL hydrochloric acid 33 % (3 hours, ultrasonication). The extracts were dried 
and the residue reconstituted with 50 µL MeOH and 500 µL 0.2 mM ammonium formate (analytical 
grade) in water. As internal standards deuterated standards of the following compounds were used, 
added as mixture of the following compounds: cocaine-d3, benzoylecgonine-d3, ethylcocaine-d3, 
morphine-d3, MAM-d3, codeine-d3, dihydrocodeine-d3, amphetamine-d6, methamphetamine-d9, 
MDMA-d5. MDEA-d6, MDA-d5, methadone-d9, EDDP-d3, methylphenidate-d9, tramadol-d3, 
oxycodone-d3, and ephedrine-d3. All deuterated standards were from ReseaChem (Burgdorf, 
Switzerland), the solvents for washing and extraction were of analysis grade and obtained from Merck 
(Darmstadt, Germany); LC-solvents were of HPLC grade and were obtained from Sigma Aldrich 
(Buchs, Switzerland). 
The LC-MS/MS apparatus was an ABSciex QTrap 3200 (Analyst software Version 1.5, Turbo V ion 
source operated in the ESI mode, gas 1, nitrogen (50 psi); gas 2, nitrogen (60 psi); ion spray voltage, 
3500V; ion source temperature, 450°C; curtain gas, nitrogen (20 psi) collision gas, medium), with a 
Shimadzu Prominence LC-system (Shimadzu CBM 20 A controller, two Shimadzu LC 20 AD pumps 
including a degasser, a Shimadzu SIL 20 AC autosampler and a Shimadzu CTO 20 AC column oven, 
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Shimadzu, Duisburg, Germany). Gradient elution was performed on a separation column (Synergi 4µ 
POLAR-RP 80A, 150x2.0 with a POLAR-RP 4x2.0 Security Guard Cartridge, (Phenomenex, 
Aschaffenburg, Germany). The mobile phase consisted of 1mM ammonium formate buffer adjusted to 
pH 3,5 with formic acid (eluent A) and acetonitrile containing 1mM ammonium formate and 1 mM 
formic acid (eluent B). The Analysis was performed in MRM mode with two transitions per analyte 
and one transition for each deuterated internal standard, respectively. According to the Society of Hair 
Testing (Society of Hair, 2004), the following cut-offs have been applied: cocaine, 500 pg/mg; 
amphetamine, 200 pg/mg; and MDMA, 200 pg/mg. 
Methods S3: Construction of cognitive domain scores 
Fifteen predefined main cognitive test parameters were z-transformed on the basis of means and 
standard deviations of the control group as published before (Vonmoos et al., 2013). If necessary, test 
scores were reversed so that high scores always indicated a better cognitive performance. These 
parameters were reduced to the four cognitive domains attention, working memory, declarative 
memory, and executive function. Furthermore, these four z-scored domains were equally integrated 
into a broad global cognitive index (GCI).  
Attention: To assess attentional capacity, we focused primarily on sustained attention by including the 
two Rapid Visual Information Processing (RVP) parameters discrimination performance A’ and total 
of hits (Jones et al., 1992). In order to diversify this domain we added the Ray Auditory Verbal 
Learning Test (RAVLT) parameter trial 1, a supraspan measure with a large attentional component 
(Lezak et al., 2004).  
Working Memory: The Spatial Working Memory (SWM) parameter number of total errors tested the 
capability to retain spatial information and to manipulate remembered items in working memory 
(Morris et al., 1988). The Letter Number Sequencing Test (LNST) measured the verbal working 
memory by summing up the number of correct responses (Wechsler, 1997). The third parameter was 
the number of correctly located patterns after the first presentation, a Paired Associates Learning 
(PAL) parameter measuring primarily a visual working memory component (Sahakian et al., 1988). 
Declarative memory: The RAVLT was administered to assess the verbal declarative memory 
performance (Helmstaedter et al., 2001). Performance was measured by the parameters learning 
performance (∑trials 1-5), delayed recall (trial 7), and an adjusted recognition performance (p(A)) 
(Helmstaedter et al., 2001). To capture the visual declarative memory, we used the two PAL 
parameters: adjusted total of errors and adjusted total of trials (Sahakian et al., 1988). 
Executive Functions: The Intra/Extra-Dimensional Set Shifting (IED) assessed visual discrimination, 
attentional set formation, maintenance, shifting, and flexibility (Downes et al., 1989). The considered 
test parameters were the total of errors and trials adjusted to the amount of completed stages. Hereby, 
we added the SWM strategy score assessing the applied heuristic strategies (Morris et al., 1988), and 
the RAVLT recall consistency, a parameter impaired in patients with prefrontal lesions(Alexander et 
al., 2003; Benedict et al., 2005; Jokeit et al., 1997) and related with measures of executive functions 
(Beebe et al., 2000). 
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Methods S4: Social cognition tasks 
In brief, the Movie for the Assessment of Social Cognition (MASC) (Dziobek et al., 2006) consists of 
a movie pausing 45 times and participants are asked about the actors’ feelings, thoughts, and 
intentions during the presented social situation in a multiple-choice format. Besides the correct 
answer, three wrong answers are presented, each reflecting a different error type: insufficient mental 
state interference (undermentalizing), excessive (overmentalizing) and non-mental state interferences 
(physical causation, no Theory-of-Mind). We analyzed these three error types separately (see 
Supplementary material, eFigure 1) as well as the MASC sum score reflecting the total number of 
correct answers. These four variables were z-transformed on the basis of means and standard 
deviations of the control group. 
The PC-assisted Multifaceted Empathy Test (MET) (Dziobek et al., 2008) contains photographs of 
everyday-life situations allowing for interpretation of the emotional mental states of the depicted 
person based on her/his facial expression and posture. By ratings on a visual analogue scale, explicit 
emotional empathy (EEE) is assessed (“How concerned are you for this person?”). Likewise, implicit 
emotional empathy (IEE) is measured by arousal ratings (“How calm/aroused does this picture make 
you feel?”). Cognitive empathy (CE) is measured by asking the participants to choose one out of four 
words to describe the person’s feeling. These three empathy parameters were also z-transformed on 
the basis of means and standard deviations of the control group. 
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Figure S1: Group comparisons for cognitive empathy, explicit and implicit emotional empathies, 
and Theory of Mind. Mean z-scores and standard errors are shown. Values corrected for years of 
education and age. Sidak post-hoc tests vs. controls: *p<.05; vs. ADHD: †p<.05, ††p<.01; vs. CU-
ADHD: ‡p<.05. Cohen’s d effect sizes for group comparisons vs. controls are shown.
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Figure S2: Group comparisons of the three error types for the assessment of 
social cognition. Mean of error types and standard errors for the assessment of 
social cognition (MASC) for cocaine users with (n=24) and without (n=30) 
ADHD, ADHD patients (n=29), and healthy controls (n=40). Cohen’s d effect 
sizes for group comparisons vs. the control group are shown. ANCOVA (with 
years of education and age as covariates) for overmentalizing (too excessive) 
yielded a main effect for group [F(3,117)=4.08, p<.01] Sidak post-hoc tests 
revealed that cocaine users with ADHD made more errors than controls (*p<.05) 
and ADHD patients (††p<.01, d=0.93) in overmentalizig. 
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Figure S3: Interaction graph for overmentalizing. Mean 
overmentalizing error scores and standard errors for the assessment 
of social cognition (MASC) over all participants (n=123). Two-
way ANCOVA (with years of education and age as covariates) 
with the fixed factors ADHD and CU revealed a significant 
interaction [F(1,117) = 4.84, p<.05] and a significant main effect 
for cocaine use (p<.01). 
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Table S1: Global cognitive index (GCI), the four cognitive domain z-scores, and neuropsychological test scores. 
Controls ADHD CU-ADHD CU+ADHD F df p 
Global Cognitive Index (GCI) -0.05 (0.11) -0.33 (0.13) -0.67 (0.12)** -1.07 (0.14)***†† 12.115 3 .000 
Neurocognitive domain scores 
Attention -0.03 (0.14) -0.28 (0.17) -0.54 (0.16) -0.82 (0.19)** 4.159 3 .008 
Working memory -0.05 (0.13) -0.29 (0.15) -0.69 (0.15)** -1.08 (0.17)***††† 8.871 3 .000 
Declarative memory -0.07 (0.16) -0.55 (0.19) -0.95 (0.18)** -1.77 (0.21)***†††‡ 14.070 3 .000 
Executive functions -0.04 (0.14) -0.19 (0.17) -0.51 (0.16) -0.6 (0.19) 2.682 3 .050 
Neuropsychological test scores 
Attention 
RVP Discrimination performance A' 0.92 (0.01) 0.91 (0.01) 0.9 (0.01) 0.89 (0.01) 2.090 3 .105 
RVP Total hits 18.64 (0.78) 17.51 (0.93) 16.78 (0.9) 15.44 (1.1) 1.973 3 .122 
RAVLT Supraspan trial 1 9.97 (0.33) 9.47 (0.39) 8.62 (0.37)* 7.99 (0.46)** 4.922 3 .003 
Working memory 
LNST Score 16.49 (0.47) 15.89 (0.56) 14.51 (0.54)* 13.2 (0.66)***† 6.246 3 .001 
SWM Total errors 17.35 (2.43) 16.59 (2.88) 26.74 (2.79) 26.55 (3.4) 3.602 3 .016 
PAL First trial memory score 16.67 (0.5) 14.95 (0.59) 15.11 (0.57) 13.15 (0.7)*** 5.783 3 .001 
Declarative memory 
RAVLT Learning performance (∑ trials 1-5) 65.59 (1.12) 63.08 (1.32) 59.56 (1.28)** 55.42 (1.56)***†† 10.138 3 .000 
RAVLT Adjusted recognition performance p(A) 0.94 (0.02) 0.91 (0.02) 0.84 (0.02)*** 0.83 (0.02)***† 9.045 3 .000 
RAVLT Delayed recall trial 7 13.92 (0.32) 13.43 (0.38) 12.73 (0.37) 11.09 (0.45)***†††‡ 8.965 3 .000 
PAL Total errors adjusted 7.06 (1.43) 11.1 (1.7) 9.1 (1.64) 18.12 (2.03)***‡‡ 6.943 3 .000 
PAL Total trials adjusted 7.67 (0.36) 8.34 (0.43) 8.11 (0.42) 10.36 (0.51)**†‡‡ 6.402 3 .000 
Executive functions 
IED Total errors adjusted 26.54 (5.4) 30.56 (6.41) 32.7 (6.21) 23.56 (7.57) .378 3 .769 
IED Total trials adjusted 97.98 (9.71) 106.15 (11.52) 108.97 (11.16) 95.16 (13.6) .319 3 .812 
SWM Strategy score 31.58 (0.86) 30.39 (1.02) 33.22 (0.99) 33.22 (1.2) 1.679 3 .175 
RAVLT Recall consistency in % 94.45 (1.36) 91.93 (1.61) 89.04 (1.56) 83.74 (1.91)***† 7.148 3 .000 
Data are estimated means and standard errors for controls (n=40), ADHD patients (29), CU-ADHD (30), and CU+ADHD (24). Statistical Test: ANCOVA over all groups with age and years of 
education as covariates. In PAL and SWM one subject is missing due to a technical failure. RVP=Rapid Visual Information Processing. RAVLT=Rey Auditory Verbal Learning Test. 
LNST=Letter Number Sequencing Task. SWM=Spatial Working Memory. PAL=Paired Associates Learning. IED=Intra-Extra Dimensional Set Shift. 
Sidak post-hoc tests: vs. controls: * p <.05, ** p <.01, *** p <.001, vs. ADHD † p <.05, †† p <.01, ††† p <.001, vs. CU-ADHD: ‡ p <.05 ‡‡ p <.01. 
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Table S2: Correlations between craving for cocaine and outcome measures 
  CCQ sum score 
Attention -0.184 
Working memory -0.182 
Declarative memory -0.147 
Executive functions -0.177 
Global cognitive Index -0.212 
METa: explicit emotional empathy -0.043 
METa: implicit emotional empathy -0.019 
METa: cognitive empathy -0.21 
MASCb: Theory-of-Mind -0.299 
BDIc sum score 0.216 
ADHD-SR sum scored 0.251 
Correlations between the CCQ sum score and measures 
of cognitive performance as well as depressive 
symptoms and ADHD scores in cocaine users (n=54) are 
shown. No significant correlations (p<.01) were found. 
a Multifaceted Empathy Test 
b Movie for the Assessment of social Cognition 
c Beck’s Depression Inventory 
d ADHD self-rating Scale; Sum of the Items 1 to 18. 
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 Table S3: Drug use patterns. 
Significant p-values are shown in bold. Statistical tests: ANOVA (all groups) and t-tests (two groups). 
Consumption per week, duration of use, and cumulative dose are averaged within the total group. 
Last consumption is averaged only for persons who used the drug within the past 6 months. In this case, sample size (n) is shown. 
aAveraged for the past six month. 
bFor cut-offs see online Methods S2, one urine sample (CU-ADHD) is missing. 
cIn tablets à 100 mg. 
Sidak post-hoc tests: vs. controls: *<.05, **<.01, ***<.001, vs. ADHD †<.05, †††<.001, vs. CU-ADHD: ‡‡‡<.001 
Controls ADHD CU-ADHD CU+ADHD Χ2 / F / t df, dferr p 
Amphetamine 
Grams per weeka 0 (0) 0 (0) 0 (0.1) 0.1 (0.3)* 3.338 3, 119 .022 
Years of use 0 (0) 0.2 (0.7) 0.8 (2.1) 2.9 (3.8)***†††‡‡ 12.277 3, 119 .000 
Cumulative dose (grams) 0 (0) 0.1 (0.4) 8.2 (22.4) 48.1 (88.9)***†††‡‡ 8.386 3, 119 .000 
Last consumption (days) 0 (0) 60.8 n=1 59.9 (49.2) n=8 82.1 (51.7) n=10 0.454 2, 16 .643 
Positive urine testingb 0 (0%) 2 (6.9%) 1 (3.4%) 1 (4.2%) 2.615 3 .455 
Hair analysis pg/mg 0 (0) 27.3 (140.7) 24.3 (83.3) 65.4 (171.4) 1.794 3, 118 .152 
MDMA 
Tablets per weeka,c 0 (0) 0 (0.1) 0.1 (0.3) 0.4 (2) 1.339 3, 119 .265 
Years of use 0 (0) 0.4 (1.2) 2.1 (3.4)* 3.7 (5.5)***††† 9.137 3, 119 .000 
Cumulative dose (tablets) 0.1 (0.4) 6.8 (22.9) 37.9 (70.6) 108.3 (383.1) 2.242 3, 119 .087 
Last consumption (days) 0 (0) 91.2 n=1 56.4 (44.3) n=9 66.4 (31.3) n=9 0.440 2, 16 .652 
Hair analysis pg/mg 0 (0) 0.9 (4.7) 406.3 (1219.8) 387.3 (967.9) 2.894 3, 118 .038 
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